By: Mike Basset From: medpagetoday.com The FDA granted marketing authorization for the ProSense Cryoablation Systemfor small, early-stage breast cancer in older women not suitable for surgery, maker IceCure announced. A minimally invasive tool that destroys tumors by freezing them, the device is indicated for women 70 years and older who have biologically low-risk tumors, no larger than 1.5 cm, and …
Risk for Second Cancer Low for Women Treated for Early, Invasive Breast Cancer
From : oncologynurseadvisor.com The risk for second primary cancers is higher for breast cancer survivors than for women in the general population; however, the risk remains low and is mostly driven by contralateral breast cancer, according to a study published online Aug. 27 in The BMJ. Paul McGale, Ph.D., from the University of Oxford in the United Kingdom, and colleagues …
Real-World Data Tie Early Breast Cancer ctDNA to Recurrence, Lower OS
By: Jax DiEugenio From: oncnursingnews.com Findings from a real-world analysis using data from the Flatiron Health Research Database linked positive circulating tumor DNA (ctDNA) with lower overall survival (OS) and higher risk of recurrence in patients with early-stage breast cancer regardless of subtype, per a presentation at the 2025 American Society of Clinical Oncology Annual Meeting. Among 4,639 patients (2.4% …
Distant Recurrence Risk in Early Breast Cancer on the Decline
By: Mike Bassett From: medpagetoday.com The long-term risk of distant recurrence for women with early breast cancer has declined significantly, a decades-long analysis of clinical trial data showed, largely a result of patients enrolling with lower-risk disease along with improved adjuvant therapy. In women with estrogen receptor (ER)-positive disease scheduled for at least 5 years of endocrine therapy, the 10-year …
New treatment approach improves recurrence-free survival in early breast cancer patients
Source: University of California – Los Angeles Health Sciences From: news-medical.net A new treatment approach that combines a targeted therapy drug with hormone therapy significantly increased the amount of time a person with stage 2 or 3 HR-positive, HER2-negative early breast cancer lives without the cancer returning, according to a new study co-led by UCLA Health Jonsson Comprehensive Cancer Center …
Managing HER2+ Early Breast Cancer: A Focus on Target Therapy
From: targetedonc.com New breast cancer diagnoses account for 31% of annual cancer diagnoses among women in the United States.1 Among those diagnoses, HER2 overexpression is observed in 25% to 30% of cases. Historically, HER2-positive (HER2+) breast cancer was considered an aggressive subtype and was associated with a poor prognosis; however, the emergence of HER2-targeted therapies such as trastuzumab has considerably …
Managing HER2+ Early Breast Cancer: Insights and Future Horizons
By: Sandra M. Swain, MD, FACP, FASCO From: targetedonc.com In this Precision Medicine Perspectives series Navigating HER2+ Early Breast Cancer: Insights, Innovations, and Future Horizons, Sandra M. Swain, MD, associate dean for research development and professor of medicine at the Georgetown University Medical Cancer, offers a an overview of available data on HER2-directed tyrosine kinase inhibitors (TKIs) and discusses how emerging data on potential …
ASTRO Updates Partial Breast Irradiation Guidance in Early Breast Cancer
By: Megan Brooks From: medscape.com The American Society for Radiation Oncology (ASTRO) has issued an updated clinical practice guideline on partial breast irradiation for women with early-stage invasive breast cancer or ductal carcinoma in situ (DCIS). The 2023 guideline, which replaces the 2017 recommendations, factors in new clinical trial data that consistently show no significant differences in overall survival, cancer-free …
Early Breast Cancer: Effect of Radiotherapy to Regional Nodes
By: Matthew Stenger From: ascopost.com As reported in The Lancet by the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), an individual patient meta-analysis has shown that more recent—but not older—trials of regional lymph node radiotherapy vs no radiotherapy in patients with early breast cancer showed benefits of radiotherapy. Study Details The study involved individual patient data from 14,324 women in …
New research finds most women diagnosed with early breast cancer can expect to become long-term survivors
By Pooja Toshniwal Paharia From: news-medical.net In a recent study published in the BMJ, researchers reported longitudinal outcomes among British women suffering from early invasive-type breast tumors as their initial tumor and those initially treated by surgical methods such as conservative surgery or mastectomy. Background Breast cancer prognosis estimates based on characteristics such as the tumor size, participant age, lymph …
- Page 1 of 2
- 1
- 2